Sinobiopharma Inc. is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004, Sinobiopharma employs more than 80 people at its corporate office and production facility in Nantong, China.

Sinobiopharma launched its extremely low-cost, Chinese patented new formulation of the pre-surgical skeletal muscle relaxant Cisatracurium Besylate on May 30, 2006. By October 2007, it had captured 80% of the Chinese market and was in use in more than 200 hospitals.

Anesthetics Product Pipeline

Cisatracurium besylate

Nondepolarizing skeletal muscle relaxant; indicated for inpatients and outpatients as an adjunct to general anesthesia; facilitates tracheal intubation, and provides skeletal muscle relaxation during surgery or mechanical ventilation in the ICU; approved by the SFDA in 2006.

Rocuronium

Nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration; indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Gantacurium chloride

New, investigational, non-depolarizing ultra-short acting neuromuscular blocker; used as an adjunct to general anesthesia to enable rapid intubation of patients undergoing surgery.

Cardiovascular Product Pipeline

Eplerenone

Blocker of aldosterone binding at the mineralocorticoid receptor;
indicated for congestive heart failure, post-myocardial infarction
and hypertension.

Perindopril

Non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor;
indicated for stable coronary artery disease hypertension.

Clevidipine butyrate

Dihydropyridine calcium channel blocker; indicated for the reduction of blood pressure when oral therapy is not feasible or desirable.

Revenue Forecast

Investment Highlights

• Leadership of CEO, Dr. Lequn Lee Huang a former manager of the Bayer Co., one of the world's largest pharmaceutical companies
• Diverse portfolio of marketed products and robust product pipeline
• Proven track record of product development and commercialization
• Strong financial management with CFO formerly of JP Morgan Chase and Smith Kline Beecham
• Patented technology for fast, low-cost synthesis of active pharmaceutical ingredients (API) enhances capability for rapid development of new drugs
• Proven R&D partners for collaborative drug discovery and established relationships with multinationals for outsourced drug development
• Nationwide sales and distribution network
• Patented technology for rapid low cost drug discovery
• Experienced management with international track record
• Flagship drug a best seller in China
• Robust product pipeline and increasingly diversified portfolio

R&D Strength

Sinobiopharma conducts research and development through Nanjing Su Ji Biotech Research Development Center and in cooperation with the Medicinal Chemistry Research Institute, Nanjing University. Both are located at Nanjing University in Nanjing. The city has emerged as one of China major biotech research and development centres. Sinobiopharma's R&D team of 18 specialists (out of a total staff of 80) are highly experienced research personnel and medical professionals. They have given the Company a strong intellectual property base with six patents (see table below), primarily in the area of new methods for synthesizing compounds at lower cost, more rapidly and/or with greater ease of use. This strong R&D capacity, coupled with Sinobiopharma's established links with multinational pharmaceutical companies makes the Company an attractive partner as a contract research organization (CRO).

Growth Strategy

Sinobiopharma has a clearly defined strategy to drive short, middle and long term growth. All drug development will leverage the Company's patented technology for fast, low-cost drug synthesis and new technology for formulation.

In the Short Term, the focus is launching drugs new to the Chinese market. The Company's patented synthesis method allows the company to develop new active pharmaceutical ingredients (API) at lower cost and new formulations that generally offer greater convenience in application and efficacy with fewer side effects.

The Middle Term will focus on exporting Active Pharmaceutical Ingredients and Drug Reformulations developed with the Company's patented technology for the global market.

The Long Term will focus on applying the technology platform to identifying candidate compounds from Traditional Chinese Medicines. Such compounds have proven their safety and efficacy over thousands of years of use. Sinobiopharma will accelerate their discovery, synthesis and formulation for pharmaceutical applications.

Sales and Distribution

Nationwide Distribution Network

Sinobiopharma has an established a nationwide sales and marketing network that distributes its products in 30 provinces and key major cities throughout China. The Company intends to expand its sales and marketing infrastructure to meet China's rapidly growing demand for safer, lower-cost, higher-efficacy drugs.

Chinese Pharmaceutical Market Growing at Record Levels

Sinobiopharma is expanding in one of the world's largest and fastest growing markets. The Chinese pharmaceutical market is among the world's largest, ranking ninth in both terms of volume and dollar value, at $9.8 billion in 2005. (MIDAS Sales Data, IMS Health, March 2006).

It is also one of the world's fastest growing. From 2001 to 2005 the Chinese pharmaceutical industry's compound annual growth rate (CAGR) was 21%, almost triple the 8%, the global average. The industry is expected to continue this rapid growth, with IMS Health projecting China to have the world's fifth largest market by 2010.

SNBP has been drifting slowly lower the last few weeks but the trading volume has picked up the last week and both the MACD and Stochastics indicators look to be oversold and have turned up the last few trading sessions. We expect more company news coming out this week and we expect this might be great timing to pick up a few shares of SNBP.

Do you homework fast on SNBP and watch for company news out this week and a futher increase in trading activity.